Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRVN
Previous Symbol
CUSIPN/A
Phone610-354-8840
Debt
Debt-to-Equity Ratio0.16
Current Ratio4.30
Quick Ratio4.30
Price-To-Earnings
Trailing P/E Ratio-0.53
Forward P/E Ratio-1.16
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.75 million
Price / Sales14.05
Cash FlowN/A
Price / CashN/A
Book Value$0.59 per share
Price / Book1.08
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-71,860,000.00
Net MarginsN/A
Return on Equity-94.85%
Return on Assets-51.80%
Miscellaneous
Employees51
Outstanding Shares82,320,000
Market Cap$55.32 million
OptionableOptionable
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) posted its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.07. The biopharmaceutical company earned $3 million during the quarter, compared to analysts' expectations of $3 million. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
6 brokers have issued 12-month price objectives for Trevena's stock. Their forecasts range from $0.75 to $15.00. On average, they expect Trevena's stock price to reach $6.35 in the next year. This suggests a possible upside of 892.2% from the stock's current price. View Analyst Price Targets for Trevena.
What is the consensus analysts' recommendation for Trevena?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevena.
Has Trevena been receiving favorable news coverage?
News stories about TRVN stock have trended neutral recently, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trevena earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Are investors shorting Trevena?
Trevena saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 8,481,679 shares, a decrease of 41.2% from the October 15th total of 14,428,796 shares. Based on an average trading volume of 3,940,966 shares, the short-interest ratio is presently 2.2 days. Currently, 14.2% of the company's shares are sold short. View Trevena's Current Options Chain.
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Paratek Pharmaceuticals (PRTK), Kamada (KMDA), Ocular Therapeutix (OCUL), Tyme Technologies (TYME), MEI Pharma (MEIP), Corvus Pharmaceuticals (CRVS), Lannett (LCI), Aldeyra Therapeutics (ALDX), ProMetic Life Sciences (PFSCF), Sienna Biopharmaceuticals (SNNA), Protagonist Therapeutics (PTGX), OASMIA PHARMACE/ADR (OASM), REDHILL BIOPHAR/S (RDHL), Newron Pharmaceuticals (NWPHF) and AcelRx Pharmaceuticals (ACRX).
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Ms. Carrie L. Bourdow, CEO, Pres & Director (Age 55)
- Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
- Dr. Jonathan Violin Ph.D., Sr. VP of Scientific Affairs & Investor Relations Officer (Age 43)
- Mr. John M. Limongelli, Chief Admin. Officer, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
- Mr. Michael Catalano, VP of Marketing
Who are Trevena's major shareholders?
Trevena's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (6.23%), BlackRock Inc. (2.46%), Northpointe Capital LLC (1.37%), Renaissance Technologies LLC (1.06%), JPMorgan Chase & Co. (0.66%) and GSA Capital Partners LLP (0.33%). View Institutional Ownership Trends for Trevena.
Which institutional investors are selling Trevena stock?
Which institutional investors are buying Trevena stock?
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $0.64.
How big of a company is Trevena?
Trevena has a market capitalization of $55.32 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.
What is Trevena's official website?
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (NASDAQ TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
